Interstitial lung disease associated to erlotinib treatment: A case report

Cases Journal

Volumn 3, Issue 2, 2010, Pages

  Del Castillo, Yolanda ^a   Espinosa, Paulina ^a   Bodí, Fernanda ^a   Alcega, Raquel ^a   Muñoz, Emma ^a   Rabassó, Carlos ^a   Castander, David ^a  

^a Hospital de Sant Pau i Santa Tecla   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CISPLATIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERLOTINIB; GANCICLOVIR; IMIPENEM; METHYLPREDNISOLONE; NAVELBINE; PREDNISONE;

ACUTE LUNG INJURY; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HYPEREOSINOPHILIA; INTERSTITIAL PNEUMONIA; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MALE; PARANEOPLASTIC SYNDROME; RESPIRATORY FAILURE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77953440694     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.1186/1757-1626-3-59     Document Type: Article

References (8)

1. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006, 107:1207-1218.
2. Blackledge G, Averbuch S: Gefitinib (Iressa, ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 2004, 90(3):566-572.
3. Bunn PA Jr, Thatcher N: Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist 2008, 13 (Suppl 1):1-4.
4. Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azoli CG: Pulmonary toxicity associated with erlotinib. Chest 2007, 132:1042-1044.
5. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 1994, 20(3):225-32.
6. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8(4):303-6.
7. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
8. Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, Marquette CH: Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007, 7:150-153.